Companies / BOC Sciences / Ensituximab
BOC Sciences

Ensituximab | BOC Sciences

Ensituximab is a chimeric monoclonal IgG1 antibody that targets a glycosylated variant of MUC5AC with specificity to colorectal and pancreatic cancer. Ensituximab was well tolerated and demonstrated modest antitumor activity in patients with heavily pretreated refractory colorectal cancer.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.